pCPA Monthly Trends & Insights – June 30, 2018

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update

The June 30, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are:

• Three negotiations were completed, while one negotiation was closed for a total of 193 completed negotiations and 26 closed negotiations;
• Eight new drug products have initiated pCPA negotiations, for a total of 47 active negotiations;
• No new drug products were added to the “No pCPA Negotiations” list, for a total of 59 products for which the pCPA has declined to negotiate – collectively or at the provincial-territorial level.

Negotiation Initiation

• Eight new drug products have initiated pCPA negotiations since the last update, for a total of 47 active negotiations.

*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation
**Original negotiation was closed in October 2017

Signals Decoded:

This month sees another file re-initiated after having been previously closed without an agreement (Kevzara), as well as a return to the negotiation table on Rituxan SC, just over a year after the completion of initial negotiations. Also of note is the initiation of negotiations for Opdivo (in combination with Yervoy) for what’s likely the first of several indications; and Maviret, a pan-genotypic treatment option for chronic HCV from AbbVie, whose other HCV therapies have not received wide public funding.

Negotiations Completed/Closed

• Three negotiations were completed since the last update, for a total of 193 completed negotiations.

*Approximation: Negotiation initiation and completion date assumed to be mid-month for the purposes of the calculation

• One negotiation was closed since the last update, for a total of 26 closed negotiations.

*Approximation: Negotiation initiation and completion date assumed to be mid-month for the purposes of the calculation

Signals Decoded:

Two single tablet regimens for HIV were completed – one successfully, Odefsey, and one closed without a LOI, Descovy. Caprelsa becomes another example of a product which was previously closed without an LOI and which has now been successfully negotiated.

Files Under pCPA Consideration

In addition to the monthly updates to the pCPA website, MORSE Consulting tracks the number of products “under pCPA Consideration” which have been reviewed by CADTH but have not yet been initiated for negotiation or closed without negotiations.

• Five new drug products received a CDEC or pERC recommendation or notification to implement in June 2018, for a total of approximately 30 products under pCPA Consideration.

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.